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Abstract
To gain a better understanding of the immunopathogenesis of tuberculous meningitis (TBM)
and identify potential diagnostic biomarkers that may discriminate TBM from other HIV-1-
associated meningitides, we assessed HIV-1 viral load levels, drug resistance patterns in
antiretroviral therapy (ART)-experienced patients with persistent viremia and soluble immu-
nological analytes in peripheral blood and cerebrospinal fluid (CSF) of HIV-1 infected
patients with TBM versus other meningitides. One hundred and three matched blood and
CSF samples collected from HIV-1 infected patients with TBM or other meningitides pre-
senting at a hospital in Durban, South Africa, from January 2009 to December 2011 were
studied. HIV-1 RNA and 28 soluble immunological potential biomarkers were quantified in
blood plasma and CSF. Viremic samples were assessed for HIV-1 drug resistance muta-
tions. There were 16 TBM, 46 probable TBM, 35 non-TBM patients, and six unclassifiable
patients. TBM and non-TBM patients did not differ in median plasma viral load but TBM
patients had significantly higher median CSF viral load than non-TBM participants (p =
0.0005). No major drug resistance mutations were detected in viremic samples. Interleukin
(IL)-1β, IL-17, platelet derived growth factor (PDGF)-BB, granulocyte colony stimulating fac-
tor (G-CSF) and cathelicidin were significantly elevated in the CNS of TBM participants com-
pared to other patients although these associations were lost after correction for false
discovery. Our data suggest that TB co-infection of the CNS is associated with enhanced
localized HIV-1 viral replication but none of the evaluated soluble immunological potential
biomarkers could reliably distinguish TBM from other HIV-associated meningitides.
PLOS ONE | https://doi.org/10.1371/journal.pone.0192060 February 2, 2018 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Seipone ID, Singh R, Patel VB, Singh A,
Gordon ML, Muema DM, et al. (2018) Tuberculous
meningitis is associated with higher cerebrospinal
HIV-1 viral loads compared to other HIV-1-
associated meningitides. PLoS ONE 13(2):
e0192060. https://doi.org/10.1371/journal.
pone.0192060
Editor: Siddappa Byrareddy, University of Nebraska
Medical Center, UNITED STATES
Received: September 8, 2017
Accepted: January 16, 2018
Published: February 2, 2018
Copyright: © 2018 Seipone et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by the Medical
Education Partnership Initiative (MEPI) seed
funding, College of Health Sciences, University of
KwaZulu-Natal; Howard Hughes Medical Institute
(grant number 55007427) to TN; the Wellcome
Trust through the Sub-Saharan African Network for
TB/HIV Research Excellence (SANTHE), a DELTAS
Introduction
HIV-1-associated opportunistic infections of the central nervous system (CNS) pose a major
public health problem in resource-limited settings. The most common opportunistic infection
in HIV1-infected individuals in sub-Saharan Africa is tuberculosis (TB) [1]. It has been
reported that co-infection with HIV-1 and tuberculosis exacerbates both diseases, although the
underlying mechanisms remain poorly understood [2]. In particular, the immunological and
biological predisposing factors for Mycobacterium tuberculosis (M.tb) dissemination and reac-
tivation in the CNS of HIV-1 infected people are unclear. Likewise, the impact of tuberculosis
in the CNS on HIV-1 replication dynamics and evolution are unknown and data are particu-
larly lacking for sub-Saharan Africa, where HIV-1 is most diverse. Furthermore, rapid and
accurate diagnosis of tuberculous meningitis (TBM) is a challenge in developing countries,
and morbidity and mortality have increased as a result of HIV/AIDS [3–5]. Therefore, there is
an urgent need to better understand the pathogenesis of HIV-1-associated TBM and to iden-
tify biomarkers that may point to possible therapeutic interventions or improved diagnosis.
It has been reported that M.tb enhances HIV replication in alveolar macrophages and
peripheral blood T cells through cytokine- and antigen-mediated cellular activation, which in
turn leads to higher viral loads and disease progression [6–8]. Although not much is known
about the interaction of HIV-1 and TB in the CNS, it has been reported that TBM is associated
with higher plasma and CSF viral loads compared to other meningitides [9,10]. The relative
concentrations of cytokines and chemokines that modulate HIV replication have been shown
to differ between the plasma and CNS compartments [11]. Some cytokines such as interleukin
(IL)-1β, IL-6, IL-8, IL-10, interferon (IFN)-γ and tumor necrosis factor (TNF)-α have also
been reported to be elevated in the CSF of TBM patients compared to other forms of meningi-
tis [12–14]. It is therefore plausible that cytokines play an integral role in the immunopatho-
genesis of TBM in HIV-1 co-infected persons and a better understanding for their role could
potentially inform therapeutic interventions or help improve the diagnosis and outcome.
Another consideration in the clinical management of TBM is the effectiveness of antiretroviral
drugs, which are known to lower viremia and improve clinical outcomes [15–17]. However,
some of the antiretroviral drugs presently available in sub-Saharan Africa have poor penetra-
tion through the blood-brain barrier [18]. This may result in viral persistence, emergence of
resistance within the CNS and ultimately neurocognitive impairment [19–21]. Regardless, sup-
pression of plasma viral load is regularly used as an indication of drug effectiveness and as a
guide in selecting treatment options [20,22].
In this study, we hypothesised that there are virological and host immunological biomark-
ers that could distinguish TBM from other meningitis. We investigated HIV-1 viral load levels
of between CSF and blood in patients infected with HIV-1 subtype C presenting with tubercu-
lous versus other meningitis and characterized HIV-1 drug resistance profiles in patients with
persistent viremia in either compartment. We also compared concentrations of soluble immu-
nological analytes in plasma and CSF amongst TBM and non-TBM patients to identify a spe-
cific TBM biomarker profile.
Methods
Study participants
Study participants were a subset of individuals with available matched blood and CSF patient
samples obtained from patients presenting with meningitides at Inkosi Albert Luthuli Central
Hospital in Durban, South Africa as previously described [22,23]. Informed written consent
was obtained from all participants, for the patients who were unable provide consent at initial
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presentation, due to an abnormal mental state, consent was obtained from a first degree rela-
tive or from the Head of Department when a lumbar puncture was clinically justified [23,24].
Participants were grouped into three different groups as follows; 1) TBM (either PCR or CSF
culture positive for M.tb (n = 16, with 15 antiretroviral therapy (ART)-naïve), the M.tb culture
and TB PCR (Roche Amplicor, Roche Diagnostics GmbH, Roche Applied Science, Mannheim,
Germany) were carried out on fresh CSF obtained by lumber puncture as previously described
[23,25]; 2) Probable TBM (clinical features of meningitis, a lumbar puncture (LP) consistent
with an aseptic meningitis, negative for other causes of meningitis, and two of the following: a
chest X-ray consistent with active pulmonary tuberculosis (PTB), a CT scan consistent with
TBM (basal enhancement or hydrocephalus and a response to anti-tuberculous therapy)
(n = 46 with 33 ART-naive); and 3) non-TBM (an alternate definite cause for meningitis iden-
tified and response to appropriate non-tuberculous therapy) (n = 35 with 22 ART-naive).
Detailed description and detection methods for the non-TBM group opportunistic infections
are described in previous publications [23,24]. Briefly, the non-TBM group consisted of
patients positive for cytomegalovirus (CMV), herpes simplex virus (HSV type 1) varicella zos-
ter virus (VZV) detected by viral PCR (Roche Amplicor), neurosyphilis was detected by fluo-
rescent treponemal antibody (FTA) test and venereal disease research laboratory (VDRL) test
if FTA was positive; cysticercal enzyme linked immunosorbent assay (ELISA), and a crypto-
coccal antigen latex agglutination test (CLAT) were also carried out [23,24]. The ELISPOT
assay (T-SPOT.TB; Oxford Immunotec, Oxford, Abingdon, UK) was used to rule out latent
TB infection in non-TBM patients as detailed in a previous publication [24]. Six of the patients
with suspected meningitis could not be classified as any of the above groups and 4 of these
were ART-naïve. Overall, 74 study participants were ART-naïve and 29 were ART-exposed
(Fig 1). The participants on ART were all on first line regimen as recommended by the South
African Antiretroviral Treatment Guidelines, which includes two nucleoside reverse transcrip-
tase inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) [26].
Regimen 1A consists of stavudine lamivudine and efavirenz; and regimen 1B is a combination
of stavudine, lamivudine and nevirapine. Routine CD4+ T-cell counts and clinical chemistry
assays performed included CSF glucose, lymphocyte counts and protein levels as previously
described [23]. Plasma samples were aliquoted and stored at -80˚C and thawed once at use.
Viral loads
Plasma and CSF HIV-1 viral RNA copies were quantified using the COBAS TaqMan HIV-1
Test, v2.0, with a dynamic detection range of 34 to 10,000,000 copies/ml (Roche Molecular
Systems, Inc. Branchburg, NJ, USA). The plasma and CSF samples of each patient were
assayed in parallel to prevent inter-assay variations.
Genotypic resistance testing
Of the 29 patients on ART, four patients had persistent viremia in both plasma and CSF, three
patients had persistent plasma viremia only and one patient had persistent viremia in the CSF
only. Persistent viremia was defined as being on treatment but with HIV-1 viral loads400
copies/ml. An in-house HIV-1 drug resistance assay was performed on the samples with per-
sistent viremia in the CSF, plasma or both. Briefly, viral RNA was extracted from both CSF
and plasma using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), followed by
cDNA synthesis and amplification of the pol gene as previously described [27]. PCR products
were then purified using the Qiagen PCR purification kit (Qiagen) and sequenced using the
Sanger method (3130XL Genetic Analyzer; Applied Biosystems, Foster City, CA, USA).
Sequences were assembled and manually edited using Sequencher software version 5.0 (Gene
Cerebrospinal HIV-1 viremia in tuberculous meningitis
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Codes Corporation, Ann Arbor, MI, USA). Clustal X version 2.0 [28] was used to align
sequences, followed by manual editing using BioEdit version 7.2.2 [29]. To ensure no cross-
contamination between samples, neighbour joining phylogenetic trees were drawn and viewed
using the Geneious software suite (Biomatters Ltd., Auckland, New Zealand). Sequences were
submitted to the Stanford Drug Resistance Database, for identification of drug resistance
mutations (DRMs) (http://hivdb.stanford.edu).
Potential biomarkers measurement
Analyte levels of paired plasma and CSF samples were measured using the Bio-Plex Pro™
27-plex Luminex kit (BioRad Laboratories Inc, Hercules, California, USA) according to the
manufacturer’s instructions, with modifications as detailed hereafter. The master standard
stock was diluted 10X, following the normal four-fold dilution of the standard as per manufac-
turer’s instructions. The panel included: pro-inflammatory cytokines; IL-1β, IL-2, IL-7, IL-9,
IL-12, IL-17, IFN-γ and TNF-α; anti-inflammatory cytokines interleukin 1 receptor antagonist
(IL-1ra), IL-4, IL-5, IL-6, IL-10, IL-13, IL-15 and tumor growth factor (TGF)-β; chemo-attrac-
tants IL-8, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein
(MIP)-1α, MIP-1β and IFNγ–induced protein (IP)-10, regulated upon activation normal T-
cell expressed and activated (RANTES) and eotaxin; growth factors granulocyte macrophage
colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), vascular
endothelial growth factor (VEGF), platelet derived growth factor (PDGF)-BB and fibroblast
growth factor (FGF)-basic. Results were read on the BioPlex MAGPIX™ reader and analyzed
Fig 1. Flow diagram of the study participants and their grouping. Participants with matched plasma and CSF
samples were included in the current study. Quantification of viral loads and potential biomarkers were performed on
all participants, then viral loads and potential biomarkers comparison analysis were restricted to definite TBM versus
non-TBM groups.
https://doi.org/10.1371/journal.pone.0192060.g001
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on the Bio-Plex Manager software 6.1 (BioRad). The levels of the antimicrobial peptide catheli-
cidin LL-37 (CAMP) were measured using an enzyme-linked immunosorbent assay (ELISA)
kit (USCN Life Science Inc., Wuhan, China). Cathelicidin LL-37 is an antimicrobial peptide
produced by neutrophils and macrophages after activation by bacteria or vitamin D [30].
Statistical analysis
Descriptive statistics are presented as medians (with interquartile ranges) or means (with stan-
dard errors). Comparison of groups for viral loads and analytes levels were done using the
Mann-Whitney test for non-parametric data in GraphPad Prism software (version 5.01;
GraphPad). Spearman rank correlation was used to determine relationships between continu-
ous variables. To elucidate whether there is a specific biomarker profile for TBM, unsupervised
hierarchical clustering (UHC) and heat maps were generated in Morpheus (https://software.
broadinstitute.org/morpheus/) using 1- (spearman rank correlation) as a measure of dissimi-
larity. Principal component analysis (PCA) was also performed to further assess the biomarker
profile for TBM. In multivariable analyses to assess the prediction of TBM by each analyte
after adjusting for other possibly confounding analytes, a logistic regression model incorporat-
ing the analytes that were significantly different in the initial Mann-Whitney test between
TBM and non-TBM groups was used. All analyses were done using GraphPad Prism software
(version 5.01; GraphPad) and STATA version 13. P<0.05 were considered significant.
Ethical approval
The research study was approved by the Biomedical Research Ethics Committee of the Univer-
sity of KwaZulu-Natal (Reference: E325/05).
Results
There was a total of 103 patients (16 TBM, 46 probable TBM, 35 non-TBM and 6 patients
could not be classified into any of these groups) and out of these 74 were ART-naïve with the
remaining 29 on ART. The median age of the participants was 32 with an interquartile range
[IQR] of 28–36 and 33 [28–38] years respectively, with the majority being male for both the
ART-naïve (60%) and those on ART (76%) (S1 Table). Forty percent of ART-naïve TBM
(n = 15) participants and 86% of the ART-naïve non-TBM (n = 22) participants were male
(p = 0.005) (Table 1). The median age of the ART-naïve (32 [IQR, 29–35]) participants did not
differ from the non-TBM ART-naïve (34 [30–37]) participants (p = 0.438) (Table 1). There
was only one TBM participant on ART hence comparison of the demographics could not be
done between the TBM and non-TBM treated participants (Table 1).
HIV-1 target cells and the immunological milieu that facilitate viral replication may differ
between peripheral blood and the CNS resulting in discordant levels of the virus in the two
compartments within an individual. Among ART-naïve individuals, comparison of plasma
and CSF viral loads showed that the median plasma viral load was 5.14 log10 copies/ml (inter-
quartile range [IQR, 4.46–5.72]), significantly higher than the median CSF viral load of 4.70
log10 copies/ml, [3.88–5.57] (p = 0.0366) (Fig 2A). There were no significant differences
between CSF and plasma viral loads for the 29 patients on ART (Fig 2B), consistent with sup-
pression of viremia by ART in the two compartments. Some participants had detectable vire-
mia above 400 copies/ml in either compartment suggesting non-adherence, emergence of
drug resistance or lack of drug penetration into the CNS.
HIV-1 viral load dynamics in the CNS in the context of opportunistic infections is poorly
understood. We investigated whether tuberculous meningitis is associated with differential
viral replication between the blood and CNS compartments. This analysis was first performed
Cerebrospinal HIV-1 viremia in tuberculous meningitis
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on ART-naïve patients by comparing definite TBM patients’ CSF and plasma viral loads. TBM
patients showed no significant viral load differences between the blood (median 5.59 log10 cop-
ies/ml [IQR, 5.00–5.98]) and CSF (5.76 log10 copies/ml [IQR, 4.85–6.19]) compartments
(p = 0.240) (Fig 2C). For patients with an alternate cause of meningitis (i.e. the non-TBM
group), plasma viremia (median 4.98 log10 copies/ml [IQR, 3.76–5.47]) was significantly
higher than CSF viremia (4.40 log10 copies/ml [IQR, 3.46–4.78]) (p = 0.031) (Fig 2D).
We next assessed whether TBM was associated with elevated CSF HIV-1 viremia as has pre-
viously been reported among ART-naïve patients [9]. Among ART-naïve patients, median
plasma viral loads did not differ significantly between the TBM (5.59 log10 copies/ml [IQR,
5.00–5.98]) and non-TBM (4.98 log10 copies/ml ([IQR, 3.76–5.47]) groups (p = 0.240) (Fig
2E). Remarkably however, in TBM patients, the median CSF viral load (5.76 log10 copies/ml,
[IQR, 4.85–6.19]) was significantly higher than the non-TBM CSF viral load (4.40 log10 copies/
ml [IQR 3.46–4.78]) (p = 0.0005) (Fig 2F). Overall, these data indicate that TBM is associated
with higher HIV-1 replication in the CNS but not in plasma although we cannot distinguish
between cause and effect due to the cross-sectional design nature of our study.
CNS inflammation may contribute to viral replication in the CNS irrespective of etiology.
Detailed findings from our study cohort on indicators of CNS pathology have been presented
elsewhere [12]. Here, we first explored the relationship between pleocytosis (a common
marker of inflammation and of disruption of the blood brain barrier, defined as>5 cells/mm3
in the CNS [31] with ART use and meningitis etiology. The TBM group had the highest
Table 1. Comparison of demographic and clinical characteristics of TBM and non-TBM study participants.
Category Characteristics Definite TBM Non-TBM P value
ART-NAIVE No of patients 15 22
Sex % male 40% 86% 0.005#
Median Age (IQR) in years 32 (29–35) 34 (30–37) 0.438
Median CD4 counts (IQR) cells/μl 78 (41–138) 161 (45–286) 0.050
Median Lymphocytes (IQR) cells/μl 5.0 (1.0–11) 2.0 (0.3–4.2) 0.031
Median Proteins (IQR) g/l 2.0 (1.9–2.7) 1.0 (0.7–1.7) 0.003
Median Glucose-CSF (IQR) nnonnmol/l nmol/l nmol/l nmol/l 1.3 (1.0–1.8) 2.3 (1.7–2.7) 0.019
% pleocytosis 47% 18% 0.080#
% with Glucose-CSF < 2.2 nmol/l 87% 67% 0.262#
% with Protein-CSF > 0.46g/l 100% 91% 0.505#
ON ART No of patients 1 13
Sex % male 100% 31% N/D
Median Age (IQR) in years 33 (N/A) 36 (33–45) N/D
Median CD4 counts (IQR) cells/ μl 81 (N/A) 130 (76–336) N/D
Median Lymphocytes (IQR) cells/ μl 2.9 (N/A) 2.1 (0.8–5.0) N/D
Median Proteins (IQR) g/l 3.3 (N/A) 0.9 (0.6–2.7) N/D
Median Glucose-CSF (IQR) nmol/l 0.6 (N/A) 1.7 (0.9–3.4) N/D
% pleocytosis 0% 7.70% N/D
% with Glucose-CSF < 2.2 nmol/l 0% 62% N/D
% with Protein-CSF > 0.46g/l 100% 92% N/D
N/D: Not determined because there was only one TBM patient on ART. N/A: Not applicable. IQR: Interquartile range. Significant differences between the groups are
shown in bold P values
Mann-Whitney test
#Fisher’s exact test
https://doi.org/10.1371/journal.pone.0192060.t001
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Fig 2. HIV-1 viral loads in plasma and cerebrospinal fluid (CSF). (A) Plasma viral loads are significantly higher than CSF viral
loads in ART-naïve participants. (B) For ART-experienced participants with meningitis, there was no significant difference in HIV-1
viral load levels when comparing plasma versus CSF. (C) HIV-1 viral loads in the CSF versus plasma of ART-naïve patients with
tuberculous meningitis (TBM), showing no significant differences between the two compartments. (D) ART-naïve non-TBM
patients had significantly higher plasma compared to CSF viral loads. (E) Plasma viral loads of ART-naïve patients with TBM versus
other meningitides are not significantly different. (F) Significantly higher HIV-1 viral loads in CSF of ART-naïve TBM patients
compared to those with other meningitides. P-values are shown for each comparison and are bolded if the differences are statistically
significant.
https://doi.org/10.1371/journal.pone.0192060.g002
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median number of lymphocytes (5.0 cells/μl, [IQR, 1.0–11.0]) compared to the non-TBM
group (2.0 cells/μl, [IQR, 0.3–4.0]) (p = 0.031). The TBM group also had the highest percentage
of patients with lymphocytic pleocytosis (47%), however, it was not statistically different from
the non-TBM group (18%) (p = 0.080) (Table 1). The median number of CSF lymphocytes
was within the normal range for the non-TBM group (2.0 cells/μl, [IQR, 0.3–4.0]) (Table 1).
Other commonly used clinical markers of CNS inflammation are CSF protein and glucose
concentrations [32]. Glucose levels of>2.2 mmol/l in the CNS are regarded as normal, with
lower levels taken as an indication of bacterial infection. Comparison within ART-naïve par-
ticipants showed that the definite TBM group had abnormal median glucose levels and the
median glucose levels (1.3 nmo/l, [IQR, 1.0–1.8]) were significantly lower than the non-TBM
group (2.3 nmol/l [IQR, 1.7–2.7]) (p = 0.019). All the TBM group patients (100%) had abnor-
mal protein levels, above the normal cut-off concentration of 0.46 g/l (Table 1). There was sig-
nificant positive correlation between the HIV-1 CSF viremia and the number of CSF
lymphocytes for both TBM patients (r = 0.518, p = 0.0240) and non-TBM patients (r = 0.410,
p = 0.0292). There was no correlation between CSF glucose, protein, or CD4 counts and CSF
viremia (S2 Table).
Among patients on antiretroviral therapy, viral load discordance between peripheral blood
and the CNS has occasionally been reported and may indicate ongoing compartmentalized
virus replication [19,21,33–35]. We sequenced the pol gene to assess for drug resistance-associ-
ated mutations in patients with persistent viremia in peripheral blood or the CSF. Four
patients (A83, A102, A128 and A138) had persistent viremia in both plasma and CSF. Patient
A83 had been on ART for 7 months, A102 for 24 months, whereas treatment duration was
unknown for A128 and A138. None of these patients showed major DRMs, however patient
A102 had the T74S Protease Inhibitor (PI)-accessory mutation in both compartments. Patients
X219, A149 and X225 had persistent viremia in plasma only and had been on treatment for 1,
28 and 24 months respectively. No DRMs or polymorphisms were present in X219. Patient
A149 harboured the T74S PI-accessory mutation and X225 had both the A98G NNRTI-non-
polymorphic accessory mutation and the T74S PI-accessory mutation. Only patient A107 had
persistent viremia in the CNS only, and this patient had been on treatment for two months.
Patient A107 had no major drug resistance mutations but had the E138A NNRTI-polymorphic
mutation. Overall, resistance profiling of the patients only showed polymorphic and accessory
mutations on 4 patients (Table 2).
Identification of immunological changes specific to particular pathogens could present an
opportunity for better understanding of pathogenesis and therapeutic interventions or
improved diagnosis. Therefore, we first compared analyte levels between compartments and
thereafter explored for potential plasma and CSF immunological biomarkers that may distin-
guish between TBM and non-TBM meningitis. Comparisons of median concentrations of
plasma and CSF analytes between TBM and non-TBM patients were performed as well as
unsupervised hierarchical clustering (UHC) and principal component analysis (PCA) to eluci-
date whether there is a specific biomarker expression profile for TBM in HIV-1 co-infected
patients.
Comparison of plasma and CSF analyte levels of all ART-naïve participants showed that the
following were significantly higher in the CSF than plasma; IL-β, IL-6, IL-8, IL-10, IL-15,
G-CSF, GM-CSF, IP-10, MCP-1, MIP-1α, MIP-1β, VEGF and cathelicidin (Table 3) however
after Bonferroni adjustment for multiple comparison IL-1β was not significant. In contrast,
the levels of IL-1ra, IL-2, IL-4, IL-5, IL-7, IL-9, IL-12, IL-17, eotaxin, FGF-b, IFN-γ, PDFG-bb,
RANTES and TNF-α were significantly higher in plasma compared to CSF, IL-1ra, IL-2 lost
significance after Bonferroni adjustment for multiple comparison. We next compared analyte
levels amongst groups (for ART-naïve patients only). There was no significant difference
Cerebrospinal HIV-1 viremia in tuberculous meningitis
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between TBM and non-TBM patients in any of the plasma analyte levels (Fig 3A). The pro-
inflammatory cytokines IL-1β and IL-17 were significantly higher in the CSF of TBM patients
compared to non-TBM patients (p = 0.0152 and p = 0.0461, respectively). The growth factors
PGDF-BB and G-CSF were also higher in CSF of TBM patients compared to non-TBM
patients (p = 0.0461 and p = 0.0242 respectively). One growth factor, GM-CSF was signifi-
cantly higher in non-TBM than TBM patients (p = 0.0407) (Fig 3B). However, upon Bonfer-
roni adjustment for multiple comparisons, none of the analytes were significantly different
between the groups. Cathelicidin was significantly elevated in the CSF of TBM patients com-
pared to non-TBM patients (p = 0.0449) (Fig 3B). We then used a multivariable logistic regres-
sion analyses to determine the predictive ability of IL-1β, IL-17, PDGF-bb, G-CSF and
cathelicidin on TBM after adjusting for each one of these analytes. There were no significant
predictions of TBM by any of the analytes. However, for every nanogram increase in CSF levels
of cathelicidin, there was a trend whereby the odds of having TBM increased by a factor of
1.376 [95% confidence intervals (0.996–1.900) p = 0.053] (S3 Table).
Unsupervised hierarchical clustering on plasma analytes did not reveal any common profile
within the TBM or non-TMB groups (Fig 4A). In the unsupervised hierarchical clustering of
CSF analytes, the samples formed 3 major clusters of 12, 27 and 6 patients each. However,
there were no significant preferential distributions of TBM or non-TBM patients to the clus-
ters, even when the analysis was limited to the ART-naïve patients in the larger clusters of 12
and 27 patients (Fishers exact test, p = 0.13) (Fig 4B). In further assessment using principal
component analyses (PCA), there was no evidence of differential clustering of patient groups
when the PCA analyses were done on either plasma or CSF analytes, suggesting lack of a strong
biomarker signature that can definitively differentiate TBM patients from non-TBM patients
(Fig 4C and 4D).
Table 2. Demographic, clinical characteristics and summary of drug resistance testing profiles of patients with persistent viremia treated with first-line antiretrovi-
ral therapy.
Participant
ID
Sex Age
(years)
Source
Compartment
CD4 count
cells/μl
Plasma and CSF viral
loads (copies/ml)
Treatment
regimen
Treatment duration
(months)
NRTI (Y/
N)
NNRTI (Y/
N)
PI (Y/
N)
A83 F 36 Plasma 245 724761 1B 7 N N N
CSF 65465 N N N
A102 F 25 Plasma 159 2912258 1A 24 N N Y
(T74S)
CSF 23088 N N Y
(T74S)
A107 F 27 CSF 234 1316 1A 2 Y
(E138A)
N N
A128 F 23 Plasma 28 211518 1B no info N N N
CSF 51013 N N N
A138 F 37 Plasma 97 1143 1B no info N N N
CSF 670 N N N
A149 F 29 Plasma 95 871 1A 28 N N Y
(T74S)
X219 M 19 Plasma 62 470 1A 1 N N N
X225 F 36 Plasma ND 1180 1A 24 N Y (A98G) Y
(T74S)
Regimen 1A: stavudine lamivudine, efavirenz; regimen 1B: stavudine, lamivudine, nevirapine; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside
reverse-transcriptase inhibitor; PI, protease inhibitor; N, no; Y, yes; no info, no information available; ND, not done.
https://doi.org/10.1371/journal.pone.0192060.t002
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Table 3. Comparison of plasma and CSF potential biomarker levels for all ART-naïve assayed participants.
Biomarker Plasma CSF P-value Adjusted P-value
IL-1β 7.260 (3.825–11.71) 9.230 (3.365–24.78) 0.0122 0.3294
IL-1ra 237.7 (134.2–363.0) 158.9 (69.47–284.2) 0.0099 0.2673
IL-2 8.830 (4.050–12.65) 6.780 (4.880–9.385) 0.0180 0.486
IL-4 3.380 (2.025–4.920) 1.740 (1.060–2.435) <0.0001 <0.0027
IL-5 24.98 (17.91–34.76) 7.720 (4.880–11.16) <0.0001 <0.0027
IL-6 17.68 (9.075–33.21) 667.8 (60.35–10083) <0.0001 <0.0027
IL-7 18.53 (11.83–26.35) 3.600 (2.275–6.775) <0.0001 <0.0027
IL-8 13.53 (7.895–22.78) 355.2 (62.30–924.9) <0.0001 <0.0027
IL-9 34.57 (21.23–40.60) 11.30 (8.095–16.18) <0.0001 <0.0027
IL-10 21.64 (12.79–33.05) 37.54 (12.17–82.56) <0.0001 <0.0027
IL-12 42.20 (19.27–56.25) 14.91 (7.260–54.12) 0.0107 0.2889
IL-13 17.37 (10.16–25.62) 16.74 (11.09–26.71) 0.3904 >0.9999
IL-15 13.00 (6.540–19.68) 28.40 (21.82–41.66) <0.0001 <0.0027
IL-17 59.92 (32.35–90.65) 18.62 (12.10–30.50) <0.0001 <0.0027
Eotaxin 48.93 (29.61–63.51) 14.38 (11.19–20.01) <0.0001 <0.0027
FGF basic 47.41 (34.75–108.9) 27.34 (22.64–57.73) <0.0001 <0.0027
G-CSF 58.97 (33.13–74.18) 99.76 (41.59–385.4) <0.0001 <0.0027
GM-CSF 20.49 (8.390–36.40) 88.93 (53.86–120.2) <0.0001 <0.0027
IFN-γ 187.0 (110.0–246.9) 82.89 (55.55–152.8) <0.0001 <0.0027
IP-10 902.0 (477.2–1793) 9800 (9800–9800) <0.0001 <0.0027
MCP-1 24.65 (16.99–38.09) 136.6 (64.25–237.8) <0.0001 <0.0027
MIP-1α 4.820 (3.300–7.445) 21.93 (6.930–43.83) <0.0001 <0.0027
PDGF-bb 774.1 (314.3–1293) 14.81 (8.395–35.29) <0.0001 <0.0027
MIP-1β 35.23 (20.81–51.58) 84.08 (34.89–179.5) <0.0001 <0.0027
RANTES 1234 (676.5–1672) 482.3 (229.0–1048) <0.0001 <0.0027
TNF-α 63.63 (30.85–87.48) 36.69 (16.90–60.31) 0.0052 0.1404
VEGF 41.98 (23.04–62.44) 64.34 (24.25–200.4) <0.0001 <0.0027
Cathelicidin 5928.9 (3281.9–7162.7) 12888 (8444.8–15499 <0.0001 -
Statistical test: Wilcoxon matched pairs signed rank test. Adjusted P values were determined by Bonferroni correction. Significant adjusted results are shown with P
values in bold
https://doi.org/10.1371/journal.pone.0192060.t003
Fig 3. Plasma and CSF biomarker levels. Comparison of potential biomarker levels in (A) plasma and (B) CSF of
ART-naïve patients with and without TBM.  p< 0.05, statistical test, Mann Whitney test.
https://doi.org/10.1371/journal.pone.0192060.g003
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Fig 4. Clustering patterns of potential biomarkers according to participant clinical status (TBM, non-TBM, ART-
naïve and ART-experienced). Hierarchical clustering heat map of potential biomarker profiles for (A) plasma analytes
and (B) CSF analytes of patients with and without TBM (on ART and not on ART). Blue represents low concentration
of biomarker below the median and red depicts high concentration of biomarker above the median value. (C) PCA
plots of biomarkers in the plasma and (D) CSF of TBM and non-TBM patients. The % of variance explained by each
PC is displayed on the respective axis.
https://doi.org/10.1371/journal.pone.0192060.g004
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Discussion
TBM is common but difficult to diagnose definitively in HIV-infected individuals. The true
incidence of TBM is not known due to lack of diagnostic tools; however, Patel et al., (2013)
reported that in the KwaZulu-Natal province of South Africa, approximately 10% of the TB
cases are TBM [36]. There is limited information on HIV-1 replication dynamics in the CNS
in TB co-infected individuals and the factors that may facilitate viral replication in this com-
partment are largely unknown especially for subtype C that dominates in sub-Saharan Africa.
Our study demonstrated that CSF HIV-1 viremia is higher in TBM versus non-TBM patients,
with no significant difference between the plasma viral loads of the two groups. Non-TBM
patients had higher plasma compared to CSF viremia, whereas no significant differences
between the compartments were noted for the TBM group (Fig 2). Several studies have
reported lower levels of HIV-1 in the CSF compared to matched plasma, primarily in patients
without opportunistic infections [37–39] and this is consistent with findings among the non-
TBM patients in our cohort. Our findings are consistent with previous studies showing that
TBM is associated with higher levels of HIV-1 RNA in the CSF compared to other meningiti-
des [9,10]. These findings suggest that TB co-infection enhances HIV-1 replication in the
CNS, consistent with studies demonstrating that TB antigens and microbial products enhance
HIV replication [40,41]. However, it is also possible that enhanced HIV replication in the CNS
predisposes to new infection or reactivation of tuberculosis in this compartment.
The TBM group had higher median number of lymphocytes than the non-TBM group,
indicative of higher CNS inflammation in TBM. The TBM group also had the highest percent-
age of patients with abnormal glucose and lowest CD4 T-cell counts (Table 1). Among the
TBM patients, the only clinical marker of CNS inflammation that correlated positively with
CSF viral loads was lymphocyte count (S2 Table). Similar to our study, it was previously
reported that TBM was characterized by lymphocytic pleocytosis, which was more severe than
in other forms of HIV-1-associated meningitis, and that the number of infiltrating lympho-
cytes correlated positively with HIV-1 viremia [9]. This may indicate that co-infection with TB
enhances the inflammation in the CNS more than other meningitides or high inflammation
caused by HIV-1 may be leading to TB co-infection. Overall, our data suggest that in TBM
there may be more target cells for intrathecal HIV replication and enhanced viral trafficking to
the CNS [31].
Discordant plasma and CSF viral loads in persons receiving ART have previously been
reported and may indicate low drug penetrance and emergence of drug resistant variants,
which may in turn lead to enhanced virus replication and associated neurological deterioration
[20,21,37,38]. In this study, there was no evidence of major DRMs in patients with persistent
viremia in either compartment, suggesting that treatment failure may be due to sub-optimal
drug adherence. One patient (A107) had persistent viremia in the CNS and not in plasma.
This patient however had only been on treatment for two months, so it may indicate slower
penetration of drugs into the CNS resulting in delayed virus suppression kinetics.
The diagnosis of TBM in the CNS poses a problem in developing countries with high HIV/
TB co-infection burden. TB culture is commonly used, but this has low sensitivity and takes
weeks before diagnosis [42]. Delay in diagnosis can lead to poor prognosis. Discovering TBM-
specific biomarkers in HIV-infected individuals is crucial for efficient clinical management of
the infection. Comparison of TBM and non-TBM cases identified CSF immunological ana-
lytes, namely IL-1β, IL-17, PDGF-BB, G-CSF and cathelicidin that were significantly elevated
in the TBM compared to non-TBM patients. Although our cohort was small, and these ana-
lytes lost statistical significance after correction for multiple comparisons, and PCA could not
identify a specific TBM specific biomarker profile, these findings may point to a potential role
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of the pro-inflammatory cytokines (IL-1β and IL-17), growth factors (PDGF-BB and G-CSF)
and the antimicrobial peptide cathelicidin in the immunopathogenesis of TBM and to their
utility as potential diagnostic biomarkers. Pro-inflammatory cytokines IL-17 and IL-1β play a
crucial role in bacterial infections. IL-17 is known to induce many inflammatory cytokines,
recruits neutrophils against extracellular bacteria and induces antimicrobial peptides in mac-
rophages. Low levels of this cytokine have been associated with impaired immunity to bacterial
infections [43,44]. IL-1β is one of the few cytokines produced by microglia cells in the CNS
and it induces activation and proliferation of astrocytes. This cytokine has been implicated in
HAD and has been shown to be highly expressed in patients with HAD, and increased produc-
tion of IL-1β following monocyte activation with toll-like receptor (TLR) ligands has been
associated with reduced odds of tuberculosis recurrence [45,46]. The growth factors PDGF
and G-CSF are produced by macrophages and endothelial cells. PDGF regulates cell growth
and division, blood vessel formation, and it can also be produced by platelets. G-CSF is a glyco-
protein that stimulates bone marrow to produce granulocytes and stem cells. This cytokine
also stimulates proliferation, differentiation and function of neutrophils [47]. Cathelicidin LL-
37 is an antimicrobial peptide produced by neutrophils and macrophages after activation by
bacteria or vitamin D [30]. Our data on cathelicidin are consistent with findings from children
with TBM who had significantly elevated CSF cathelicidin levels in the TBM compared to
non-TBM patients [30], but there are other notable differences for other potential biomarkers
analysed, perhaps a reflection of differences between adults and children in disease immuno-
pathogenesis. Nevertheless, our data highlight the potential for CSF biomarkers to distinguish
between TBM and other HIV-1-associated meningitides in adults.
Conclusion
TB co-infection of the CNS is associated with enhanced HIV-1 replication and disruption of
the BBB, characterized by lymphocytic CNS inflammation. In this study cohort, there was no
evidence of compartment-specific viral escape from antiretroviral therapy. Our study suggests
that in TBM, the CNS may serve as a compartment for enhanced HIV replication and may
therefore serve as a reservoir. Our study failed to identify soluble immunological biomarkers
that could reliably distinguish between TBM from other HIV-associated meningitides
although a few, including IL-1β, IL-17, PDGF-BB, G-CSF and cathelicidin may require further
evaluation in future studies to improve the understanding of the immunopathogenesis or
improved diagnosis of HIV-1-associated adult TBM.
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